期刊文献+

硫酸沙丁胺醇口腔崩解片人体生物等效性研究 被引量:5

Bioavailability of Salbutamol Sulfate Orally Disintegrating Tablets in Healthy Subjects
下载PDF
导出
摘要 目的 :比较硫酸沙丁胺醇口腔崩解片和普通片的人体生物利用度。方法 :18名健康志愿受试者随机交叉单剂口服硫酸沙丁胺醇口腔崩解片和普通片 ,用高效液相色谱法测定血药浓度 ,以3p97程序计算药动学参数和生物利用度。结果 :硫酸沙丁胺醇口腔崩解片和普通片体内药 -时曲线符合二室模型 ,崩解片和普通片Cmax 分别为 (17 65±6 48)ng/ml和 (16 60±6 21)ng/ml,Tmax 分别为 (1 92±1 18)h和 (2 03±1 17)h ,AUC0~24 分别为 (127 23±32 41)ng/(h·ml)和 (131 42±37 73)ng/(h·ml) ,相对生物利用度为 (99 32±15 58) %。结论 OBJECTIVE:To study the relative bioavailability and pharmacokinetics of salbutamol sulfate orally disinteˉgrating tablets.METHODS:A single dose of8mg salbutamol sulfate orally disintegrating tablets or commercial salbutamol tablets was administered in a randomized crossover design in18volunteers and the plasma concentrations of salbutamol were determined by HPLC.The pharmacokinetic parameters were calculated with3p97pharmacokinetic program and the bioequivˉalency was evaluated.RESULTS:The concentration-time curve of two preparations fitted to two-compartment model.The peak plasma levels(C max )of salbutamol sulfate orally disintegrating tablet and commercial salbutamol sulfate tablet were(17.65±6.48)ng/ml and(16.60±6.21)ng/ml,respectively.The peak time(T max )were(1.92±1.18)h and(2.03±1.17)h and AUC 0~24 were(127.23±32.41)ng/(h·ml)and(131.42±37.73)ng/(h·ml),respectively.The relative bioavailability of salbu_ tamol sulfate orally disintegrating tablet was(99.32±15.58)%.CONCLUSION:The results of two one-side tests suggests that salbutamol sulfate orally disintegrating tablet is bioequivalent to the commercial salbutamol tablet.
出处 《中国药房》 CAS CSCD 2004年第9期551-553,共3页 China Pharmacy
关键词 硫酸沙丁胺醇 口腔崩解片 药动学 生物等效性 salbutamol sulfate orally disintegrating tablet pharmacokinetics bioequivalency
  • 相关文献

参考文献3

二级参考文献13

  • 1[1]Evans ME, Paterson JW, Richards AJ, et al. Pharmacokinetics of inhaled salbutamol in asthmatic patients [J]. Br J Pharmacol, 1971,43(2):466-467.
  • 2[2]Walker SR, Evans ME, Richards AJ, et al. The clinical pharmacology of oral and inhaled salbutamol [J]. Clin Pharmacol Ther, 1972,13(6):861-867.
  • 3[3]Newnham DM, McDevitt DG, Lipworth BJ. Comparison of the extrapulmonary β2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhalers and modified actuator device [J]. Br J Clin Pharmacol, 1993,36(5):445-450.
  • 4[4]Gupta RN, Fuller HD, Dolovich MB. Optimization of a column liquid chromatographic procedure for the determination of plasma salbutamol concentration [J]. J Chromatogr B, 1994,654(2):205-211.
  • 5[5]Emm T, Lesko LJ, Leslie J. Determination of albuterol in human serum by reversed-phase high-performance liquid chromatography with electrochemical detection [J]. J Chromatogr, 1988,427(1):188-194.
  • 6[6]Wong BJO, Hargeave FE. Bioequivalence of metered-dose inhaled medications [J]. J Allergy Clin Immunol, 1993,92(3):373-379.
  • 7[7]Chrystyn H. Standards for bioequivalence of inhaled products [J]. Clin Pharmacokinet, 1994,26(1):1-6.
  • 8[8]Lipworth BJ. Pharmacokinetics of inhaled drugs [J]. Br J Clin Pharmacol, 1996,42(6):697-705.
  • 9[9]Morgan DJ, Paull JD, Richmond BH. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate [J]. Br J Clin Pharmacol, 1986,22(5):587-593.
  • 10[10]Clark DJ, Smith JG, Clark G, et al. Lung bioavailability of generic and innovator formulations of inhaled salbutamol [J]. Eur Respir J, 1995,8(Suppl 19):259s-259s.

共引文献15

同被引文献20

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部